Clinical Trial

Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients.

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 19, 2024 (before its estimated December 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment. In this study phase, a traditional "3+3" trial design is employed for dose escalation.
Trial Details
NCT Number NCT06375161
Lead Sponsor Shanghai Tongji Hospital, Tongji University School of Medicine
Conditions B Cell Malignancies
Enrollment 12 participants
Start Date 2023-12-11
Primary Completion 2025-12-10 (estimated)
Study Completion 2039-12-10 (estimated)
Updated on ClinicalTrials.gov 2024-04-19